About the Kesimpta Dosing Calculator
Guidance on using this tool and understanding its outputs for Kesimpta (ofatumumab) administration. This information is for educational purposes and is not a substitute for clinical judgment.
About
The Kesimpta (ofatumumab) Dosing Calculator is an educational resource for healthcare professionals. It helps generate patient-specific dosing schedules based on the standard administration protocol. It can create a full initial schedule for a new patient or provide guidance on how to manage a missed dose during either the loading or maintenance phase of treatment.
Outputs
The tool provides two distinct types of results based on the calculation mode selected:
1. New Patient Dosing Schedule
For new patients, the calculator generates a detailed, date-specific table for the first year of therapy. This output clearly outlines the dates for the three weekly loading doses and the subsequent monthly maintenance doses, aiding in patient scheduling and education.
2. Missed Dose Action Plan
For patients who miss a dose, the tool provides a clear recommendation. It advises on how to proceed based on whether the missed dose was part of the loading or maintenance phase and, crucially, how long it has been since the last administered dose.
How to Use
Follow these simple steps to get a calculation:
- For a New Patient: Select the "New Patient Dosing Schedule" mode. Enter the desired date for the first dose (Week 0). The calculator will generate the complete schedule for the initial loading doses and subsequent monthly maintenance doses.
- For a Missed Dose: Select the "Missed Dose Management" mode. Enter the date of the last dose the patient actually received. Specify whether the missed dose was a "Loading Dose" or a "Maintenance Dose". The tool will provide the recommended next step.
Dosing Overview
Kesimpta is administered as a 20 mg subcutaneous injection according to the following schedule:
| Phase | Timing | Dose |
|---|---|---|
| Initial Dose 1 (Loading) | Week 0 | 20 mg |
| Initial Dose 2 (Loading) | Week 1 | 20 mg |
| Initial Dose 3 (Loading) | Week 2 | 20 mg |
| First Maintenance Dose | Week 4 | 20 mg |
| Subsequent Maintenance Doses | Monthly thereafter | 20 mg |
Switching Therapies
This calculator does not provide guidance for patients switching to Kesimpta from other disease-modifying therapies. The timing of the first Kesimpta dose relative to the last dose of a prior therapy should be determined by a healthcare professional based on the mechanism of action and half-life of the previous medication.
Missed Dose Guidance
The tool's logic for managing a missed dose is based on the prescribing information:
- Missed Loading Dose: If a loading dose is missed, it should be administered as soon as possible. Do not wait for the next scheduled dose. The timing of subsequent doses should be adjusted to maintain the recommended intervals between doses.
- Missed Maintenance Dose: If a monthly maintenance dose is missed, it should be administered as soon as possible. The next dose should then be scheduled one month from the date this make-up dose was given, establishing a new monthly schedule.
Re-initiation Warning: If the time between two maintenance doses is 4 months or longer, treatment with Kesimpta must be re-initiated. This requires restarting the full loading dose schedule (Week 0, 1, and 2) before resuming monthly maintenance doses.
Safety Alerts
Before initiating Kesimpta, healthcare professionals must perform required screenings and be aware of administration protocols:
- Hepatitis B Virus (HBV) Screening: All patients must be screened for HBV (HBsAg and anti-HBc) before starting treatment.
- Serum Immunoglobulins: Quantitative serum immunoglobulin levels should be assessed prior to initiation.
- Administration: The first injection should be performed under the guidance of a healthcare professional. Injection-related reactions are possible, most commonly occurring within 24 hours of the first dose.
Frequently Asked Questions
1. What is the re-initiation rule for a missed Kesimpta dose?
If a patient goes 4 months or longer between maintenance doses, they must restart the therapy from the beginning with the full three-dose loading schedule (Week 0, 1, 2) before resuming monthly injections.
2. How does the calculator determine the next dose after a missed maintenance dose?
If the gap is less than 4 months, the calculator advises taking the missed dose immediately. The new monthly schedule is then based on the date of this make-up dose, not the original schedule.
3. What should I do if a patient misses one of the first three loading doses?
The missed loading dose should be given as soon as possible. The subsequent loading dose intervals (e.g., 7 days) should be maintained from the new date, which will shift the overall schedule.
4. Does this calculator provide a supply or prescription estimate?
No, this tool is strictly for scheduling administration dates. It does not calculate medication quantity, supply needs, or costs.
5. Can this tool be used for dose adjustments or for other conditions?
No. The calculator is based on the standard 20 mg dose for approved indications. It should not be used for off-label dosing or for patients requiring dose adjustments.
6. Is the information from this calculator a substitute for the official Prescribing Information?
Absolutely not. This is an educational tool. All dosing decisions must be based on clinical judgment and verified against the most current official Prescribing Information for Kesimpta.
7. Does the calculator account for daylight saving time changes?
The calculator operates on calendar dates. It adds a set number of days (7, 14) or months (1) to the input date, which is not affected by daylight saving time.
8. Does the calculator store any patient health information?
No. The tool is self-contained and runs entirely in your browser. It does not collect, store, or transmit any personal or health information.
References
- KESIMPTA® (ofatumumab) Prescribing Information. U.S. Food and Drug Administration.
- Kesimpta (ofatumumab) European public assessment report (EPAR). European Medicines Agency.
- Dosing & Administration for KESIMPTA® (ofatumumab). Novartis Pharmaceuticals Corporation.
- Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020;383(6):546-557.
I am a Registered Pharmacist under the Pharmacy Act, 1948, and the founder of PharmacyFreak.com. I hold a Bachelor of Pharmacy degree from Rungta College of Pharmaceutical Science and Research. With a strong academic foundation and practical knowledge, I am committed to providing accurate, easy-to-understand content to support pharmacy students and professionals. My aim is to make complex pharmaceutical concepts accessible and useful for real-world application.
Mail- Sachin@pharmacyfreak.com